Tive source of NSPCs for use in cell therapy research and
Tive source of NSPCs for use in cell therapy research and development. In Japan, iPSC stocks [9, 10] are being established from peripheral blood* Correspondence: [email protected] Equal contributors 2 Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan Full list of author information is available at the end of the articlemononuclear cells (PBMCs) of donors with a range of immunologically preferable genotypes. However, before such cells can be used in clinical applications, the safety of transplanted cells must be determined. Transplant safety issues include infection, immunological problems such as SB 202190 custom synthesis rejection, complications resulting from drugs such as immunosuppressants, and complications resulting from unexpected migration or transplant behavior [11, 12]. As for stem cells, which have the potential to develop into a variety of mature tissue types, efforts must be made to manage the risk of contamination by undifferentiated pluripotent cells, or the transformation of graft-derived intermediate progenitors into malignant tumor cells [13?6]. Malignant tumors occasionally exhibit immature and embryonic-like structures, and normal embryonic cells?2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28045099 and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Sugai et al. Molecular Brain (2016) 9:Page 2 ofshare some characteristics with malignant tumor cells; i.e., normal developing tissues in which stem cell multiplication occurs exhibit significant mitotic activity, similar to that in malignant tumors. Under such conditions, the cellular mitotic index is not helpful in distinguishing stem cells from malignant tumors. NSPCs for transplantation therapies also exhibit characteristics of less developmentally mature cells, and thus it is necessary to classify the histology of transplanted cells by their developmental characteristics in order to distinguish them from the malignant transformation of transplants. In the present study, we induced NSPCs from integration-free human peripheral blood mononuclear cell (PBMC)-derived iPSCs (iPSC-NSPCs) using two different protocols, compared their in vitro properties, and also compared their in vivo histology by transplanting them into intact striata or injured spinal cords of immunodeficient (NOD/Shi-scid, IL-2R null (NOG) [17] or NOD/scid [18]) mice. Our histological categorization may serve as a useful tool for predicting and describing the performance of NSPCs for future quality evaluations of cell products for future transplantation therapy.the NSPCs, suggesting that all three integration-free human PBMC-derived iPSCs examined had been induced to differentiate into NSPCs under both protocols via passage 7. We further characterized and compared the properties of each induced NSPCs by microarray expression analysis and found that all EB- and NR-NSPCs from the same iPSCs had profiles that closely resembled each other, with correlations of > 97.3 (Fig. 1e a.
